Stock Price

About the Company

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.






Total Revenue




Market Capitalization


Price/Earning ratio

Company News

Analyzing AlloVir Inc.’s (ALVR) Stock Behavior

1d ago, source: stocksregister

AlloVir Inc. (NASDAQ:ALVR) concluded the trading at $6.66 on Thursday, August 11 with a fall of -22.65% from its closing price on previous day. Taking a look at stock we notice that its last check on ...

Here’s Our Rant About AlloVir Inc. (ALVR)

3d ago, source: newsheater

AlloVir Inc. (NASDAQ:ALVR) went up by 13.96% from its latest closing price compared to the recent 1-year high of $26.41. The company’s stock price has collected 44.67% of gains in the last five ...

Research Analysts Issue Forecasts for AlloVir, Inc.’s FY2022 Earnings (NASDAQ:ALVR)

12d ago, source: Defense World

Stock analysts at SVB Leerink upped their FY2022 EPS estimates for AlloVir in a research report issued to clients and ...

AlloVir Reports Second Quarter 2022 Financial Results

8d ago, source: Stockhouse

“In the first half of 2022, AlloVir made great progress advancing our pipeline of off-the-shelf, multi-virus specific T cell therapies, especially with our lead candidate, posoleucel. The preliminary ...

Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know

10d ago, source: Nasdaq

Shares of AlloVir, Inc. (ALVR) have gained 24.6% over the past four weeks to close the last trading session at $5.53, but there could still be a solid upside left in the stock if short-term price ...

Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares?

12d ago, source: Yahoo Finance

Every investor in AlloVir, Inc. (NASDAQ:ALVR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning ...

AlloVir (NASDAQ:ALVR) Price Target Cut to $23.00

12d ago, source: Defense World

AlloVir (NASDAQ:ALVR – Get Rating) had its price objective decreased by SVB Leerink from $30.00 to $23.00 in a research note ...

Research Analysts Issue Forecasts for AlloVir, Inc.’s FY2022 Earnings (NASDAQ:ALVR)

12d ago, source: ETF Daily News

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) – Equities research analysts at SVB Leerink upped their FY2022 earnings estimates for shares of AlloVir in a report issued on Wednesday, July 27th.

My Portfolio